OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
OptimizeRx CorporationNASDAQ: OPRX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $2.71M (cash outflow) rose 361.3% year over year, ahead of the +124.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 21.5% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.
Context
- Financing cash flow amounted to 8.0% of revenue in FY2025, up 2.7 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +361.3% holds above the trailing-twelve-month pace of +124.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (8.8M) USD
- Year-over-year change
- -79.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.8M) | -79.1% |
| FY2024 | 2024-12-31 | (4.91M) | -117.4% |
| FY2023 | 2023-12-31 | 28.22M | +248.9% |
| FY2022 | 2022-12-31 | (18.95M) | -125.6% |
| FY2021 | 2021-12-31 | 73.92M | — |
Financing Cash Flow vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +124.8% is the 4th highest of 10, against a peer median of +86.9%.
- Financing cash flow amounts to 10.2% of revenue for OPRX, versus a peer median of 16.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $723.38M USD | +13967.7% | +995.9% | 18455.2% | |
| LTM Mar 2026 | CA$279.19M CAD | +434.6% | +154.4% | — | |
| LTM Mar 2026 | $51.96M USD | -65.2% | +78.1% | 21.8% | |
| LTM Mar 2026 | $46.34M USD | +308.7% | — | 57.1% | |
| LTM Mar 2026 | $29.03M USD | -1.6% | +4.3% | 21.2% | |
| LTM Mar 2026 | $17.39M USD | +86.9% | -34.2% | 12.5% | |
| LTM Mar 2026 | $10.92M USD | +124.8% | -22.6% | 10.2% | |
| LTM Mar 2026 | $6.15M USD | -68.3% | — | 1.8% | |
| LTM Mar 2026 | $2.26M USD | -98.0% | -33.5% | 1.8% | |
| LTM Feb 2026 | $590K USD | +110.3% | -46.8% | 0.7% | |
| Peer median (excluding OPRX) | — | +86.9% | +4.3% | 16.9% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 378.08K | (11.44M) | (17.57M) | (20.11M) | 5.13M |
| Depreciation & Amortization | 1.97M | 2.02M | 2.4M | 4.33M | 4.33M |
| Deferred Income Tax | 0 | 0 | 0 | 1.45M | 1.21M |
| Stock-Based Compensation | 5.49M | 15.75M | 13.72M | 11.47M | 6.96M |
| Change in Working Capital | (7.19M) | 3.96M | (15.55M) | 921K | 816K |
| Accounts Receivables | (6.99M) | 2.28M | (8.71M) | (2.17M) | 460K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (603.09K) | 555.4K | 195K | (72K) | (520K) |
| Other Working Capital | 408.65K | 1.12M | (7.03M) | 3.16M | 876K |
| Other Non-Cash Items | 80K | 363.51K | 9.76M | 6.83M | 264K |
| Operating Cash Flow | 726.04K | 10.65M | (7.24M) | 4.89M | 18.72M |
| Capital Expenditures | (486K) | (244.57K) | (871K) | (112K) | (58K) |
| Acquisitions (Net) | 0 | (2M) | (80.41M) | 0 | 0 |
| Purchases of Investments | 0 | (55.93M) | (162.78M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 218.71M | 0 | 0 |
| Other Investing Activities | (385.68K) | (163.56K) | (774K) | (338K) | 126K |
| Investing Cash Flow | (486K) | (58.18M) | (25.34M) | (450K) | 68K |
| Debt Repayment | 0 | 0 | 36.02M | (4M) | (8M) |
| Common Stock Issued | 70.67M | 0 | 0 | 0 | 352K |
| Common Stock Repurchased | 0 | (20.02M) | (7.52M) | (911K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.25M | 1.07M | (278K) | 0 | (1.15M) |
| Financing Cash Flow | 73.92M | (18.95M) | 28.22M | (4.91M) | (8.8M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.16M | (66.47M) | (4.36M) | (472K) | 9.99M |
| Free Cash Flow | 240.04K | 10.41M | (8.11M) | 4.78M | 18.66M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.